Xponance Inc. Grows Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Xponance Inc. grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 33.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 35,694 shares of the medical equipment provider’s stock after acquiring an additional 8,945 shares during the quarter. Xponance Inc.’s holdings in Zimmer Biomet were worth $4,344,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ZBH. Vanguard Group Inc. boosted its stake in Zimmer Biomet by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock worth $2,954,843,000 after purchasing an additional 3,695,510 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after buying an additional 852,186 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Zimmer Biomet by 2.3% during the first quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock worth $556,244,000 after buying an additional 96,028 shares during the period. Morgan Stanley grew its holdings in shares of Zimmer Biomet by 80.5% during the fourth quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock valued at $395,560,000 after buying an additional 1,384,068 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Zimmer Biomet by 4.9% during the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock valued at $345,690,000 after buying an additional 144,147 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Up 0.1 %

ZBH stock opened at $119.43 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $149.25. The stock has a market cap of $24.54 billion, a price-to-earnings ratio of 24.42, a PEG ratio of 2.19 and a beta of 1.01. The business’s 50-day moving average is $126.33 and its 200 day moving average is $119.22.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.88 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 19.63%.

Analyst Ratings Changes

A number of research firms recently commented on ZBH. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a report on Friday, February 23rd. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Barclays increased their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. Truist Financial upped their price target on shares of Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a report on Friday, February 9th. Finally, Evercore ISI lifted their price objective on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.